Differences between the Framingham and D:A:D risk models for cardiovascular risk assessment in HIV-positive patients on antiretroviral therapy: an experience in a Colombian Caribbean population
DOI:
https://doi.org/10.24265/horizmed.2021.v21n4.08Keywords:
HIV infections, Cardiovascular models, Cardiovascular risk, Highly active antiretroviral therapy, Caribbean regiónAbstract
Objective: To assess the five- and ten-year cardiovascular disease risk in HIV-positive patients on antiretroviral therapy, using the Framingham risk score and the Data collection on adverse effects of anti-HIV drugs (D:A:D) study. Materials and methods: An observational prospective cross-sectional study. HIV-positive patients on antiretroviral treatment from a referral center for HIV patients were included in the study between January 1 and April 30, 2019. A five- and ten-year cardiovascular risk assessment was performed using the Framingham risk score and the D:A:D study. Additionally, both risk models were compared through statistical models. Results: The study population consisted of 159 patients with a mean age of 48.90 years ± 9.90. The mean cardiovascular risk according to the five-year Framingham risk score was 2.70 % ± 2.80, the ten-year Framingham risk score was 6.10 % ± 5.70, the five-year D:A:D study was 3.50 % ± 4.10, the ten-year D:A:D study was 6.90 % ± 7.70, and the ten-year Framingham risk score recalculated for Colombia (multiplied by 0.75) was 4.50 % ± 4.20. Using a logistic regression model, it was determined that the ten-year D:A:D study provided the greatest number of variables significantly related to a high cardiovascular risk. Conclusions: The study showed a significant difference between the risk models. Both the five- and ten-year D:A:D study provided a better cardiovascular disease risk estimation than the five- and ten-year Framingham model.
Downloads
References
ONUSIDA. Informe sobre la epidemia mundial de SIDA, 2020 [Internet]. 2021. Disponible en: https://www.unaids.org/es
ONUSIDA. País: Colombia [Internet]. 2021. Disponible en: https://www.unaids.org/es/regionscountries/countries/colombia
Fondo Colombiano de Enfermedades de Alto Costo. Situación del VIH/SIDA en Colombia 2020 [Internet]. Bogotá; 2020. Disponible en: https://cuentadealtocosto.org/site/vih/vih-sida-en-colombiaretos-y-apuestas-en-salud/#:~:text=En%20Colombia%2C%20los%20casos%20reportados,36%25% 20por%20cada%20100.000%20habitantes
Delaney M. History of HAART – the true story of how effective multi-drug therapy was developed for treatment of HIV disease. Retrovirology. 2006; 3(Suppl 1): S6.
Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J. 2014; 35(21): 1373-81.
World Health Organization. Cardiovascular diseases (CVDs), 2016 [Internet]. WHO; 2017. Disponible en: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
D'Agostino RB, Pencina MJ, Massaro JM, Coady S. Cardiovascular Disease Risk Assessment: Insights from Framingham. Glob Heart. 2013; 8(1): 11-23.
Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte ADA, Wit SD, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. Eur J Cardiovasc Prev Rehabil. 2010; 17(5): 491-501.
Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al. An updated prediction model of the global risk of cardiovascular disease in HIV positive persons: The Data collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2016; 23(2): 214-23.
Ministerio de Salud. Guía de práctica clínica basada en la evidencia científica para la atención de la infección por VIH/Sida en adolescentes (con 13 años de edad o más) y adultos [Internet]. Bogotá; 2014. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/GPC-corta-VIHADOLESCENTES-ADULTOS-final.pdf
Muñoz OM, Rodriguez NI, Ruiz A, Rondón M. Validación de los modelos de predicción de Framingham y PROCAM como estimadores del riesgo cardiovascular en una población colombiana. Rev Colomb Cardiol. 2014; 21(4): 202-12.
Beltrán SLV, Gualtero SM, Quiroga C, Garzón JR, Mendivelson EL, Tamara JR, et al. Evaluación y manejo del riesgo cardiovascular en infección por VIH. Consenso de expertos ACIN. Infectio. 2019; 23(Supl1): 73-91.
Centre for Excellence for Health, Immunity and Infection. The HIV pharmacovigilance. Risk assessment tool system [Internet]. CHIP; 2021. Disponible en: http://www.chip.dk/Tools
Raposeiras-Roubín S, Triant V. Cardiopatía isquémica en el VIH: profundizando en el conocimiento del riesgo cardiovascular. Rev Esp Cardiol. 2016; 69(12): 1204-13.
Asociación Médica Mundial. Declaración de Helsinki de la AMM – Principios Éticos para las investigaciones médicas en seres humanos [Internet]. AMM; 2017. Disponible en: https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principioseticos-para-las-investigaciones-medicas-en-seres-humanos/
Ministerio de Salud. Resolución N °. 8430 de 1993 [Internet]. Bogotá; 1993. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/ RESOLUCION-8430-DE-1993.PDF
Ministerio de Salud y Protección Social. Guía de Práctica Clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias en la población mayor de 18 años [Internet]. Bogotá; 2014. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/IETS /GPCDislipidemi-completa.pdf
Muller E, Godoy S, Gimeno A. Risk factors for cardiovasvular disease in HIV/AIDS patients treated with highly active antiretroviral therapy (HAART) in the central-southern region of the state of Paraná-Brazil. Ciênc Saúde Colet. 2019; 24(5): 1903-14.
Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010; 201(3): 318-30.
Nan C, Shaefer M, Urbaityte R, Oyee J, Hopking J, Ragone L, et al. Abacavir use and risk for Myocardial Infarction and Cardiovascular events: pooled analysis of data from clinical trials. Open Forum Infect Dis. 2018; 5(5): ofy086.
Lundgren J, Mocroft A, Ryom L. Contemporary protease inhibitors and cardiovascular risk. Curr Opin Infect Dis. 2018; 31(1): 8-13.
Stein JH, Currier JS, Hsue PY. Arterial disease in patients with human immunodeficiency virus infection: what has imaging taught us?. JACC Cardiovasc Imaging. 2014; 7(5): 515-25.
Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte Ad, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356(17): 1723-35.
Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS. 2008; 22(18): 2409-18.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
